AFT sees 24% hike in sales  

Flagship Maxigesic products and Australian OTC business contribute the most to latest half yearly results Maxigesic manufacturer AFT Pharmaceuticals has reported higher bottom-line profit and revenue after continued robust demand for its combo painkiller both in Australasia and internationally. In its latest half-yearly results, it reported a 24% increase in sales from existing drugs, new

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Dispensing-only product likely sold to consumers: TGA
Next Another diabetes drug scarce until end 2024